Pavel Burda

941 total citations
18 papers, 672 citations indexed

About

Pavel Burda is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Pavel Burda has authored 18 papers receiving a total of 672 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Pavel Burda's work include Acute Myeloid Leukemia Research (10 papers), Epigenetics and DNA Methylation (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Pavel Burda is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Epigenetics and DNA Methylation (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Pavel Burda collaborates with scholars based in Czechia, United States and United Kingdom. Pavel Burda's co-authors include Tomáš Stopka, Peter Laslo, Petra Bašová, Vít Pospíšil, Marek Trněný, Hana Klamová, Kateřina Machová Poláková, Michal Pešta, J Bartoš and Jana Moravcová and has published in prestigious journals such as Blood, PLoS ONE and Oncogene.

In The Last Decade

Pavel Burda

17 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pavel Burda Czechia 10 469 293 201 113 87 18 672
Jason G. Harb United States 12 385 0.8× 191 0.7× 245 1.2× 74 0.7× 168 1.9× 30 570
Garrett W. Rhyasen United States 8 288 0.6× 139 0.5× 217 1.1× 205 1.8× 65 0.7× 11 555
Germán Navarro Spain 8 403 0.9× 188 0.6× 149 0.7× 58 0.5× 36 0.4× 8 555
Luisa Tomasello United States 14 351 0.7× 260 0.9× 73 0.4× 56 0.5× 71 0.8× 25 480
Marjan Geugien Netherlands 10 415 0.9× 128 0.4× 215 1.1× 66 0.6× 71 0.8× 13 605
Isabella Spinello Italy 12 320 0.7× 248 0.8× 102 0.5× 123 1.1× 29 0.3× 15 492
Daniel P. Sejas United States 10 475 1.0× 130 0.4× 146 0.7× 85 0.8× 48 0.6× 10 641
M Zipeto United States 9 575 1.2× 167 0.6× 102 0.5× 82 0.7× 32 0.4× 13 674
Rodolphe F. Taby United States 6 572 1.2× 160 0.5× 150 0.7× 41 0.4× 52 0.6× 8 662
Andrew Volk United States 11 387 0.8× 84 0.3× 165 0.8× 114 1.0× 45 0.5× 25 547

Countries citing papers authored by Pavel Burda

Since Specialization
Citations

This map shows the geographic impact of Pavel Burda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pavel Burda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pavel Burda more than expected).

Fields of papers citing papers by Pavel Burda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pavel Burda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pavel Burda. The network helps show where Pavel Burda may publish in the future.

Co-authorship network of co-authors of Pavel Burda

This figure shows the co-authorship network connecting the top 25 collaborators of Pavel Burda. A scholar is included among the top collaborators of Pavel Burda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pavel Burda. Pavel Burda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Burda, Pavel, et al.. (2024). Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events. Molecular Metabolism. 88. 102016–102016. 1 indexed citations
2.
Bašová, Petra, et al.. (2022). Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents. International Journal of Molecular Sciences. 23(12). 6729–6729. 4 indexed citations
3.
Burda, Pavel, Tomáš Kalina, Veronika Kanderová, et al.. (2021). Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining. Frontiers in Oncology. 11. 744373–744373. 7 indexed citations
4.
Burda, Pavel, et al.. (2021). The Rate of Cellular Energy Production of Muscle Cells Is Attenuated By Carnitine Intracellular Deficiency Caused By Imatinib Treatment. Blood. 138(Supplement 1). 3609–3609. 1 indexed citations
5.
Burda, Pavel, Filipp Savvulidi, Rossana Trotta, et al.. (2018). BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 103(12). 2016–2025. 37 indexed citations
6.
Burda, Pavel, et al.. (2016). GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia. PLoS ONE. 11(3). e0152234–e0152234. 18 indexed citations
7.
Burda, Pavel, Katarzyna E. Kolodziej, Jeroen Demmers, et al.. (2016). Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: Evidence for co-repressor functions. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 1859(12). 1515–1526. 10 indexed citations
8.
Bašová, Petra, Michal Pešta, J Bartoš, et al.. (2014). Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 14(1). 448–448. 142 indexed citations
9.
Bašová, Petra, Vít Pospíšil, Filipp Savvulidi, et al.. (2013). Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene. 33(39). 4735–4745. 23 indexed citations
10.
Burda, Pavel, Vít Pospíšil, Monika Beličková, et al.. (2012). 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia. 26(8). 1804–1811. 36 indexed citations
11.
Poláková, Kateřina Machová, Hana Klamová, Pavel Burda, et al.. (2011). Expression patterns of microRNAs associated with CML phases and their disease related targets. Molecular Cancer. 10(1). 41–41. 116 indexed citations
12.
Burda, Pavel, Petra Bašová, Vojtěch Kulvait, et al.. (2011). MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 117(14). 3816–3825. 117 indexed citations
13.
Burda, Pavel, Peter Laslo, & Tomáš Stopka. (2010). The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia. 24(7). 1249–1257. 133 indexed citations
14.
Burda, Pavel, Juraj Kokavec, Petra Bašová, et al.. (2009). PU.1 Activation Relieves GATA-1–Mediated Repression of Cebpa and Cbfb during Leukemia Differentiation. Molecular Cancer Research. 7(10). 1693–1703. 21 indexed citations
15.
Stopka, Tomáš, Pavel Burda, Juraj Kokavec, et al.. (2009). MicroRNA Mir-155 and Myb Proto-Oncogene Family Members Cooperate in Pathogenesis of Chronic Lymphocytic Leukemia.. Blood. 114(22). 58–58. 4 indexed citations
16.
Pospíšil, Vít, Pavel Burda, Juraj Kokavec, et al.. (2008). Transcription Factors PU.1 and EGR2 Inhibits the Oncogenic Microrna Cluster Mir-17-92 during Macrophage Differentiation. Blood. 112(11). 473–473. 1 indexed citations
17.
Stopka, Tomáš, Juraj Kokavec, Vít Pospíšil, et al.. (2007). Mutual Regulatory Loop between miR-155 and PU.1 Is a Candidate Pathogenesis Factor in CLL.. Blood. 110(11). 1130–1130. 1 indexed citations
18.
Burda, Pavel, Juraj Kokavec, Vít Pospíšil, et al.. (2007). Fog1 and Cebpa Are DNA Targets of GATA-1/PU.1 Antagonism during Leukemia Differentiation.. Blood. 110(11). 4121–4121.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jason G. Harb Breakdown of academic impact, for papers by Garrett W. Rhyasen Breakdown of academic impact, for papers by Germán Navarro Breakdown of academic impact, for papers by Luisa Tomasello Breakdown of academic impact, for papers by Marjan Geugien Breakdown of academic impact, for papers by Isabella Spinello Breakdown of academic impact, for papers by Daniel P. Sejas Breakdown of academic impact, for papers by M Zipeto Breakdown of academic impact, for papers by Rodolphe F. Taby Breakdown of academic impact, for papers by Andrew Volk
Rankless by CCL
2026